ZA200407011B - Combination of organic compounds - Google Patents

Combination of organic compounds Download PDF

Info

Publication number: ZA200407011B
Authority: ZA; South Africa
Prior art keywords: pharmaceutically acceptable; acceptable salt; glp; sup; group
Prior art date: 2002-03-22

Application number

ZA200407011A

Other languages

English (en)

Inventor

Damon Robert Edson

Hughes Thomas Edward

Burkey Bryan

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-22

Filing date

2004-09-02

Publication date

2007-01-31

2004-09-02 Application filed by Novartis Ag filed Critical Novartis Ag

2007-01-31 Publication of ZA200407011B publication Critical patent/ZA200407011B/en

Links

150000002894 organic compounds Chemical class 0.000 title description 2
150000003839 salts Chemical class 0.000 claims description 57
230000003914 insulin secretion Effects 0.000 claims description 36
239000003623 enhancer Substances 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 20
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 20
206010020772 Hypertension Diseases 0.000 claims description 17
229960002797 pitavastatin Drugs 0.000 claims description 16
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 16
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 15
229960003765 fluvastatin Drugs 0.000 claims description 15
201000010065 polycystic ovary syndrome Diseases 0.000 claims description 15
208000035475 disorder Diseases 0.000 claims description 14
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 13
229960002855 simvastatin Drugs 0.000 claims description 13
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 12
229960000698 nateglinide Drugs 0.000 claims description 12
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 12
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 11
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 11
229940122355 Insulin sensitizer Drugs 0.000 claims description 11
229960005370 atorvastatin Drugs 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 11
239000003112 inhibitor Substances 0.000 claims description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims description 8
108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 8
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 8
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 8
229960005110 cerivastatin Drugs 0.000 claims description 8
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 8
229960004844 lovastatin Drugs 0.000 claims description 8
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 8
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 8
208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
229960002965 pravastatin Drugs 0.000 claims description 8
229960000672 rosuvastatin Drugs 0.000 claims description 8
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 8
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 7
229960002354 repaglinide Drugs 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 6
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims description 6
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 6
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 6
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 6
101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 claims description 6
206010022489 Insulin Resistance Diseases 0.000 claims description 6
208000008589 Obesity Diseases 0.000 claims description 6
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 6
229960001466 acetohexamide Drugs 0.000 claims description 6
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 6
229960003362 carbutamide Drugs 0.000 claims description 6
VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 6
229960001761 chlorpropamide Drugs 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
229960004580 glibenclamide Drugs 0.000 claims description 6
229960000346 gliclazide Drugs 0.000 claims description 6
229960004346 glimepiride Drugs 0.000 claims description 6
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 6
229960001381 glipizide Drugs 0.000 claims description 6
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 6
229960003468 gliquidone Drugs 0.000 claims description 6
229960003236 glisoxepide Drugs 0.000 claims description 6
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 claims description 6
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 6
DVQVBLBKEXITIK-UHFFFAOYSA-N glybuthiazol Chemical compound S1C(C(C)(C)C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 DVQVBLBKEXITIK-UHFFFAOYSA-N 0.000 claims description 6
229950011569 glybuthiazol Drugs 0.000 claims description 6
NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 claims description 6
229950008290 glyhexamide Drugs 0.000 claims description 6
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 claims description 6
229960004440 glymidine Drugs 0.000 claims description 6
RHQSNARBXHRBNP-UHFFFAOYSA-N glypinamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 RHQSNARBXHRBNP-UHFFFAOYSA-N 0.000 claims description 6
229950009188 glypinamide Drugs 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 6
229960003365 mitiglinide Drugs 0.000 claims description 6
WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 claims description 6
229950008557 phenbutamide Drugs 0.000 claims description 6
229960002277 tolazamide Drugs 0.000 claims description 6
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 6
229960005371 tolbutamide Drugs 0.000 claims description 6
ARSTYWCBFCDLSO-UHFFFAOYSA-N 1-(3-aminophenyl)sulfonyl-3-butylurea Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC(N)=C1 ARSTYWCBFCDLSO-UHFFFAOYSA-N 0.000 claims description 5
-1 3-hydroxy-1-adamantyl Chemical group 0.000 claims description 5
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 5
102400000325 Glucagon-like peptide 1(7-36) Human genes 0.000 claims description 5
102000004316 Oxidoreductases Human genes 0.000 claims description 5
108090000854 Oxidoreductases Proteins 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 5
208000029078 coronary artery disease Diseases 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
229940100389 Sulfonylurea Drugs 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
208000032928 Dyslipidaemia Diseases 0.000 claims description 3
208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
208000001647 Renal Insufficiency Diseases 0.000 claims description 3
230000001258 dyslipidemic effect Effects 0.000 claims description 3
208000003532 hypothyroidism Diseases 0.000 claims description 3
230000002989 hypothyroidism Effects 0.000 claims description 3
208000017169 kidney disease Diseases 0.000 claims description 3
201000006370 kidney failure Diseases 0.000 claims description 3
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims description 3
238000007634 remodeling Methods 0.000 claims description 3
230000004083 survival effect Effects 0.000 claims description 3
GKBWKSJWXJMEEQ-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2SCC1 GKBWKSJWXJMEEQ-UHFFFAOYSA-N 0.000 claims description 2
239000000556 agonist Substances 0.000 claims description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
229960003105 metformin Drugs 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims 4
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
229940123934 Reductase inhibitor Drugs 0.000 claims 1
TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 6
230000001771 impaired effect Effects 0.000 description 5
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 5
206010048554 Endothelial dysfunction Diseases 0.000 description 4
208000002705 Glucose Intolerance Diseases 0.000 description 4
230000008694 endothelial dysfunction Effects 0.000 description 4
201000009104 prediabetes syndrome Diseases 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000002792 vascular Effects 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
239000003098 androgen Substances 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
208000000509 infertility Diseases 0.000 description 3
230000036512 infertility Effects 0.000 description 3
231100000535 infertility Toxicity 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
201000000736 Amenorrhea Diseases 0.000 description 2
206010001928 Amenorrhoea Diseases 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
208000010228 Erectile Dysfunction Diseases 0.000 description 2
206010020112 Hirsutism Diseases 0.000 description 2
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
206010036049 Polycystic ovaries Diseases 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
231100000540 amenorrhea Toxicity 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
208000022831 chronic renal failure syndrome Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
206010061989 glomerulosclerosis Diseases 0.000 description 2
201000001881 impotence Diseases 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
206010000021 21-hydroxylase deficiency Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010000591 Acrochordon Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010063075 Cryptogenic cirrhosis Diseases 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010027339 Menstruation irregular Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000035175 Oligomenorrhea Diseases 0.000 description 1
206010030295 Oligomenorrhoea Diseases 0.000 description 1
206010033157 Ovarian enlargement Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
201000010272 acanthosis nigricans Diseases 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000036626 alertness Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
208000003816 familial cirrhosis Diseases 0.000 description 1
208000010706 fatty liver disease Diseases 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000001788 irregular Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
208000025661 ovarian cyst Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000007863 steatosis Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200407011A 2002-03-22 2004-09-02 Combination of organic compounds ZA200407011B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36675202P	2002-03-22	2002-03-22

Publications (1)

Publication Number	Publication Date
ZA200407011B true ZA200407011B (en)	2007-01-31

Family

ID=28454819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200407011A ZA200407011B (en)	2002-03-22	2004-09-02	Combination of organic compounds

Country Status (19)

Country	Link
US (2)	US20040002519A1 (es)
EP (1)	EP1523316A2 (es)
JP (1)	JP2005526788A (es)
KR (1)	KR20050012720A (es)
CN (2)	CN101537182A (es)
AR (1)	AR039090A1 (es)
AU (1)	AU2003209745B2 (es)
BR (1)	BR0308613A (es)
CA (1)	CA2479880A1 (es)
EC (1)	ECSP045307A (es)
IL (1)	IL163929A0 (es)
MX (1)	MXPA04009227A (es)
NO (1)	NO20044487L (es)
PE (1)	PE20040291A1 (es)
PL (1)	PL371723A1 (es)
RU (1)	RU2004131535A (es)
TW (2)	TW200810743A (es)
WO (1)	WO2003080070A2 (es)
ZA (1)	ZA200407011B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE422884T1 (de) *	2002-06-03	2009-03-15	Novartis Pharma Gmbh	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
ES2295816T3 (es)	2003-01-14	2008-04-16	Arena Pharmaceuticals, Inc.	Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
CN1812983A (zh)	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
CA2535619A1 (en)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
KR20130105741A (ko) *	2003-11-17	2013-09-25	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
EP1722780A4 (en) *	2003-11-26	2008-12-17	Univ Duke	METHOD FOR PREVENTING OR TREATING GLAUCOMA
JP2007513991A (ja) *	2003-12-16	2007-05-31	ノバルティスアクチエンゲゼルシャフト	メタボリック症候群の処置のためのスタチンの使用
US7666899B2 (en) *	2004-05-11	2010-02-23	Kissei Pharmaceutical, Co. Ltd.	Pharmaceutical composition for treatment of lipid metabolism disorder
KR100648825B1 (ko) *	2005-02-22	2006-11-24	한국유나이티드제약 주식회사	당뇨병 환자의 동맥경화증 예방을 위한 혈당강하제, 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛
ES2477868T3 (es) *	2005-04-22	2014-07-18	Alantos Pharmaceuticals Holding, Inc.	Inhibidores de dipeptidil peptidasa-IV
ME02005B (me)	2005-09-14	2012-08-31	Takeda Pharmaceuticals Co	Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
SG166829A1 (en)	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2007091623A1 (ja) *	2006-02-08	2007-08-16	Kurume University	メグリチニド類を含有する肝臓線維化予防用医薬組成物
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
DK2305263T3 (da) *	2007-06-07	2012-10-22	Novartis Ag	Stabiliserede amorfe former af imatinibmesylat
JP2011125218A (ja) *	2008-04-11	2011-06-30	Signpost Corp	糖尿病患者のフェニルアラニン誘導体系薬物感受性予測方法
JP5662475B2 (ja)	2009-12-30	2015-01-28	ビーシーワールドファーム．カンパニーリミテッド	メトホルミン及びロスバスチンを含む医薬組成物
EP2619198A1 (en)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013077819A1 (en) *	2011-11-23	2013-05-30	Mahmut Bilgic	Pharmaceutical formulations comprising nateglinide
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
TWI748945B (zh) *	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
CN109758429A (zh) *	2019-02-22	2019-05-17	安徽联谊药业股份有限公司	一种格列齐特缓释片及其制备方法
JP2023521388A (ja) *	2020-04-08	2023-05-24	ラトガース，ザステートユニバーシティオブニュージャージー	脂肪肝疾患に対する修飾キスペプチン受容体作用薬
CN114099520A (zh) *	2021-12-31	2022-03-01	中国药科大学	格列喹酮用于制备治疗溃疡性结肠炎的药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
TWI260321B (en) *	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU2336001A (en) *	1999-12-22	2001-07-03	Merck Frosst Canada & Co.	Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
EP1125579A3 (en) *	2000-01-18	2003-01-02	Pfizer Products Inc.	Uses of agrp-melanocortin receptor binding modulating compounds
JP2004513076A (ja) *	2000-07-25	2004-04-30	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病治療で有用なｎ−置換インドール類
PE20020323A1 (es) *	2000-08-22	2002-06-13	Novartis Ag	COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)

2003
- 2003-03-20 TW TW096126852A patent/TW200810743A/zh unknown
- 2003-03-20 AR ARP030100986A patent/AR039090A1/es unknown
- 2003-03-20 TW TW092106182A patent/TW200305415A/zh unknown
- 2003-03-20 PE PE2003000279A patent/PE20040291A1/es not_active Application Discontinuation
- 2003-03-21 JP JP2003577896A patent/JP2005526788A/ja not_active Withdrawn
- 2003-03-21 RU RU2004131535/15A patent/RU2004131535A/ru unknown
- 2003-03-21 CA CA002479880A patent/CA2479880A1/en not_active Abandoned
- 2003-03-21 KR KR10-2004-7014249A patent/KR20050012720A/ko not_active Withdrawn
- 2003-03-21 EP EP03744834A patent/EP1523316A2/en not_active Withdrawn
- 2003-03-21 AU AU2003209745A patent/AU2003209745B2/en not_active Ceased
- 2003-03-21 IL IL16392903A patent/IL163929A0/xx unknown
- 2003-03-21 WO PCT/EP2003/002978 patent/WO2003080070A2/en not_active Ceased
- 2003-03-21 CN CNA2009100028010A patent/CN101537182A/zh active Pending
- 2003-03-21 PL PL03371723A patent/PL371723A1/xx not_active Application Discontinuation
- 2003-03-21 MX MXPA04009227A patent/MXPA04009227A/es active IP Right Grant
- 2003-03-21 CN CNA038066556A patent/CN1642559A/zh active Pending
- 2003-03-21 BR BR0308613-5A patent/BR0308613A/pt not_active IP Right Cessation
- 2003-03-21 US US10/393,798 patent/US20040002519A1/en not_active Abandoned
2004
- 2004-09-02 ZA ZA200407011A patent/ZA200407011B/en unknown
- 2004-09-22 EC EC2004005307A patent/ECSP045307A/es unknown
- 2004-10-20 NO NO20044487A patent/NO20044487L/no unknown
2006
- 2006-08-01 US US11/497,130 patent/US20070027197A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101537182A (zh)	2009-09-23
MXPA04009227A (es)	2004-11-26
AU2003209745A1 (en)	2003-10-08
NO20044487L (no)	2004-12-20
ECSP045307A (es)	2004-10-26
AU2003209745B2 (en)	2007-05-17
US20070027197A1 (en)	2007-02-01
PL371723A1 (en)	2005-06-27
EP1523316A2 (en)	2005-04-20
CA2479880A1 (en)	2003-10-02
JP2005526788A (ja)	2005-09-08
AR039090A1 (es)	2005-02-09
TW200305415A (en)	2003-11-01
WO2003080070A2 (en)	2003-10-02
RU2004131535A (ru)	2005-06-10
US20040002519A1 (en)	2004-01-01
PE20040291A1 (es)	2004-07-02
WO2003080070A3 (en)	2004-03-25
KR20050012720A (ko)	2005-02-02
CN1642559A (zh)	2005-07-20
IL163929A0 (en)	2005-12-18
TW200810743A (en)	2008-03-01
BR0308613A (pt)	2005-03-01

Publication	Publication Date	Title
ZA200407011B (en)	2007-01-31	Combination of organic compounds
EP2300031B1 (en)	2017-09-20	Methods and compositions for oral administration of exenatide
AU664710B2 (en)	1995-11-30	A method for treatment of metabolic disorders
AU748679B2 (en)	2002-06-13	Compositions comprising D-chiro-inositol for treating metabolic diseases characterized by hyperinsulinemia, hyperandrogenism, hyperlipidemia and/or anovulation
US8017652B2 (en)	2011-09-13	Activators of peroxisome proliferator-activated receptors
IE63470B1 (en)	1995-04-19	Use of sertraline for the treatment of premature ejaculation
Guay	1998	Repaglinide, a novel, short‐acting hypoglycemic agent for type 2 diabetes mellitus
US20040034065A1 (en)	2004-02-19	Combination
CN101175494B (zh)	2011-07-13	用于糖/脂质代谢异常的预防/治疗剂
TW200800212A (en)	2008-01-01	Administration of dipeptidyl peptidase inhibitors
NZ556545A (en)	2009-03-31	Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
US8106081B2 (en)	2012-01-31	Combination of organic compounds useful for treating diabetes
Suh et al.	2003	Pharmacokinetics and pharmacodynamics of azosemide
TWI248814B (en)	2006-02-11	Compositions comprising D-chiro inositol and lipid lowering compounds
WO2002012177A1 (en)	2002-02-14	Composition of metformin with succinic acid or salts thereof and method for treating diabetes
KR101262123B1 (ko)	2013-05-14	지질 대사 이상의 예방 또는 치료용 의약 조성물
AU2007201989A1 (en)	2007-05-24	Combination comprising an HMG-CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer
TW200305408A (en)	2003-11-01	Substituted imidazolidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them
JPWO2003047591A1 (ja)	2005-04-14	肺高血圧症予防治療剤
Hussar et al.	2019	2019 New Drug Update
TWI308870B (en)	2009-04-21	Pharmaceutical composition for the prevention or delay of the progression to overt diabetes
US20040242485A1 (en)	2004-12-02	Compositions and methods for the amelioration of leptin resistance
Robaczyk et al.	2006	The effects of lanreotide administration vs unilateral adrenalectomy on disease activity in gip-dependent cushing’s syndrome
JPWO2001080854A1 (ja)	2003-07-22	ペルオキシゾーム増殖剤活性化受容体の活性化剤
JP2001288092A (ja)	2001-10-16	血糖低下剤